SCHEMBL5137380

SCHEMBL5137380

CCCCN(Cc1cc(C)c(O)c(C)c1)Cc1c(-c2ccc(F)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
CRHR1 P34998 2/20 0.39
TSHR P16473 5/20 0.37
KDM4E B2RXH2 6/20 0.36
ALDH1A1 P00352 6/20 0.36
CYP3A4 P08684 6/20 0.36
HPGD P15428 6/20 0.36
HSD17B10 Q99714 6/20 0.36
BCHE P06276 3/20 0.36
HDAC1 Q13547 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ATP4A P20648 2/20 0.35
ATP4B P51164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774335 0.94 C5AR1 (0.44) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5136142 0.92 C5AR1 (0.42) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5134693 0.91 C5AR1 (0.45) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5135730 0.91 C5AR1 (0.41) C5AR1CRHR1TSHR
SCHEMBL5134784 0.91 C5AR1 (0.40) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5138064 0.90 C5AR1 (0.43) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5136727 0.90 ATP4A (0.40) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5135240 0.89 C5AR1 (0.42) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5136574 0.89 C5AR1 (0.46) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5136250 0.89 DRD2 (0.43) C5AR1CRHR1TSHRBCHEHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed